Cefaclor is named as an intervention in 2 current clinical trials in our China and Spain registers. 2 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Children's Hospital of Fudan University (1). The most-studied condition is Biliary Atresia. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis
NCT05398679 · ClinicalTrials.gov ↗ · Endocarditis Infective
|
Phase 4 | Recruiting | Fundacion Clinic per a la Recerca Biomédica | Spain |
|
Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
NCT05925309 · ClinicalTrials.gov ↗ · Biliary Atresia, Cholangitis, Anti-Bacterial Agents
|
Not applicable | Recruiting | Children's Hospital of Fudan University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Cefaclor. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci
2026-526149-91-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 3 | Authorised | Friedrich-Schiller-Universitaet Jena | Germany |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
4 single-substance products containing Cefaclor on the HPRA medicines list.
| Lead sponsor | Trials |
|---|---|
| Children's Hospital of Fudan University | 1 |
| Fundacion Clinic per a la Recerca Biomédica | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Spain | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our China and Spain registers name Cefaclor as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in China and 1 with sites in Spain. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Children's Hospital of Fudan University (1) and Fundacion Clinic per a la Recerca Biomédica (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 4 single-substance products containing Cefaclor, for example Distaclor 125 mg/5 ml Granules for Oral Suspension (Flynn Pharma Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 3 entries for Cefaclor: 3 German notices. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cefaclor works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cefaclor works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cefaclor (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.